Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0I6QZ
|
||||
| Drug Name |
Org-37663
|
||||
| Synonyms |
Org-37663
|
||||
| Indication | Unspecified | Investigative | [1559976] | ||
| Target and Pathway | |||||
| Target(s) | Estrogen receptor | Target Info | Modulator | ||
| Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | ||||
| Signaling events mediated by HDAC Class II | |||||
| Plasma membrane estrogen receptor signaling | |||||
| LKB1 signaling events | |||||
| Regulation of Telomerase | |||||
| ATF-2 transcription factor network | |||||
| AP-1 transcription factor network | |||||
| FOXM1 transcription factor network | |||||
| Validated nuclear estrogen receptor alpha network | |||||
| Signaling mediated by p38-alpha and p38-beta | |||||
| FOXA1 transcription factor network | |||||
| References | |||||
| Ref 1559976 | The selective estrogen receptor alpha agonist Org 37663 induces estrogenic effects but lacks antirheumatic activity: a phase IIa trial investigating efficacy and safety of Org 37663 in postmenopausal female rheumatoid arthritis patients receiving stable background methotrexate or sulfasalazine.Arthritis Rheum.2010 Feb;62(2):351-8. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.